NCT07372040

Add-on Diuretics in Acute Decompensated Heart Failure

Clinical Study Comparing Empagliflozin, Acetazolamide, and Metolazone as Add-on Therapies to Loop Diuretics in Acute Decompensated Heart Failure

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 66 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of this study is to compare the efficacy and safety of empagliflozin, acetazolamide, and metolazone as add-on therapies to loop diuretics in patients with acute decompensated heart failure.

Conditions

• Acute Decompensated Heart Failure

Interventions

Type	Name	Description
DRUG	empagliflozin	Empagliflozin may augment the natriuretic and aquaretic actions of loop diuretics in patients with acute decompensated heart failure and it does not typically cause electrolyte disturbances and has been shown to improve outcomes in patients with heart failure
DRUG	Acetazolamide	Acetazolamide can augment the action of loop diuretics in patients with acute decompensated heart failure
DRUG	metolazone	Metolazone can augment the action of loop diuretics in patients with acute decompensated heart failure

Timeline

• Start date: 2026-02-01
• Primary completion: 2027-02-01
• Completion: 2027-02-01
• First posted: 2026-01-28
• Last updated: 2026-02-04

Locations

1 site across 1 country: Egypt